EIR GlaxoSmithKline Biologicals SA Feb 2000

James Maclaughlin FDA, Kirsten Vadheim FDA$595.00 - Available Now

FDA investigators audited the GlaxoSmithKline Biologicals SA - Rixensart, Belgium facility and issued inspectional observation (via FDA 483) on 25 Feb 2000.

Product details

  • Category:
  • Inspection end: 25 Feb 2000
  • Location: Rixensart, Belgium
  • FEI: 3002875226
Add To Cart